Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of Ruxolitinib & Acute Graft-Versus-Host Disease (acute GVHD), Ruxolitinib is approved by the FDA and EMA for steroid‑refractory Acute Graft-Versus-Host Disease (acute GVHD), not for all acute GVHD but specifically for cases failing corticosteroids (1, 2).
The clinical phase III trial NCT02913261 revealed that Ruxolitinib therapy resulted in notable improvements in efficacy outcomes for patients with steroid-refractory Acute Graft-Versus-Host Disease (acute GVHD). However, it was associated with a…